Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:INMBNASDAQ:LRMRNASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.06+1.2%$1.64$1.43▼$4.93$206.34M1.57154,381 shs136,708 shsINMBINmune Bio$7.65+0.3%$7.49$4.32▼$10.50$176.63M1.55275,940 shs519,274 shsLRMRLarimar Therapeutics$2.57-4.3%$2.12$1.61▼$11.20$162.31M0.79785,304 shs562,453 shsMURAMural Oncology$2.59+1.0%$2.30$0.95▼$4.74$44.81M3.361.30 million shs66,958 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+17.65%+22.16%-14.64%-57.23%INMBINmune Bio0.00%+2.14%+9.48%-4.15%-13.01%LRMRLarimar Therapeutics0.00%+16.52%+26.42%-6.94%-72.05%MURAMural Oncology0.00%-2.29%-2.66%-29.48%-23.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.2017 of 5 stars3.52.00.00.00.00.81.3INMBINmune Bio1.8417 of 5 stars3.60.00.00.02.61.70.6LRMRLarimar Therapeutics2.0441 of 5 stars3.61.00.00.03.71.70.0MURAMural Oncology2.6404 of 5 stars3.35.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$12.00481.40% UpsideINMBINmune Bio 3.17Buy$22.80198.23% UpsideLRMRLarimar Therapeutics 3.11Buy$19.67666.73% UpsideMURAMural Oncology 2.60Moderate Buy$13.00402.90% UpsideCurrent Analyst Ratings BreakdownLatest MURA, INMB, LRMR, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.00 ➝ $26.003/25/2025LRMRLarimar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/25/2025LRMRLarimar TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M7.32N/AN/A$2.12 per share0.97INMBINmune Bio$50K3,514.25N/AN/A$2.07 per share3.69LRMRLarimar TherapeuticsN/AN/AN/AN/A$1.86 per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)INMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%7/30/2025 (Estimated)LRMRLarimar Therapeutics-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)MURAMural Oncology-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)Latest MURA, INMB, LRMR, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/24/2025Q4 2024LRMRLarimar Therapeutics-$0.29-$0.45-$0.16-$0.45N/AN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86INMBINmune BioN/A2.592.59LRMRLarimar TherapeuticsN/A13.1013.10MURAMural OncologyN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%INMBINmune Bio12.72%LRMRLarimar Therapeutics91.92%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%INMBINmune Bio35.20%LRMRLarimar Therapeutics4.50%MURAMural Oncology2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableLRMRLarimar Therapeutics3064.03 million61.57 millionOptionableMURAMural Oncology11917.27 million17.01 millionOptionableMURA, INMB, LRMR, and ACIU HeadlinesRecent News About These CompaniesBlackRock Reveals 1.58% Holding in Mural OncologyJune 5, 2025 | msn.comCincinnati hospital honors late doctor with mural tributeMay 24, 2025 | local12.comGoldman Sachs adjusts positions in Mural OncologyMay 21, 2025 | investing.comMural Oncology Announces Number of Relevant Securities in IssueMay 19, 2025 | globenewswire.comBlackRock discloses stake in Mural Oncology plcMay 15, 2025 | investing.comLongtime Lawrence artist Louis Copt, known for Kansas landscape paintings, diesMay 10, 2025 | www2.ljworld.comBlackRock discloses stake in Mural OncologyMay 3, 2025 | investing.comGoldman Sachs discloses stake in Mural OncologyMay 3, 2025 | investing.comMural Oncology plc Opening Position Disclosure Under Irish Takeover RulesApril 30, 2025 | quiverquant.comFORM 8.1(a) & (b) - Mural Oncology plcApril 30, 2025 | globenewswire.com‘Final mark on his legacy’: Wood County artists dedicate work to muralist who died in JanuaryApril 30, 2025 | msn.comLuka Dončić donates entire cost of restoring vandalized Kobe Bryant mural in downtown Los AngelesApril 29, 2025 | msn.com“There is a life afterwards”: New downtown Dallas mural honors cancer survivorsApril 29, 2025 | keranews.orgParkwood Master Fund Ltd - Form 8.3 - Mural Oncology PlcApril 24, 2025 | uk.finance.yahoo.comForm 8.3 - Mural Oncology plcApril 22, 2025 | finance.yahoo.comBoston-area cancer research lab to cease drug trials, lay off 117April 22, 2025 | msn.comMass. biotech company cuts 90% of workforceApril 17, 2025 | msn.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcApril 17, 2025 | markets.businessinsider.comMural Oncology to discontinue nemvaleukin development, reduce staff by 90%April 16, 2025 | markets.businessinsider.comMURA Soars as it Explores Strategic Options Post Cancer Study FailuresApril 16, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMURA, INMB, LRMR, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$2.06 +0.02 (+1.18%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.INmune Bio NASDAQ:INMB$7.64 +0.02 (+0.31%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Larimar Therapeutics NASDAQ:LRMR$2.57 -0.11 (-3.99%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Mural Oncology NASDAQ:MURA$2.58 +0.03 (+0.98%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
